Companies formed

Since 1987, Oxford University Innovation has been responsible for creating spinout companies based on academic research generated within and owned by the University of Oxford, and in recent years has spun out 15-20 new companies every year.

Over £2.5bn in external investment has been raised by Oxford University Innovation spinouts since 2010, and ten of our current portfolio are currently listed in London and New York.

The creation of new spinout companies, most of which are listed below, also channels millions of pounds back into University research, benefits local economic development and has created many new jobs in the region.

Drug/Vaccine Delivery.

Incorporated in October 1994

Origin: Oxford University

Software enabled system for orthopaedic care pathway management, implant safety monitoring and patient reported outcome delivery.

Incorporated in March 2017

Origin: Oxford University, NDORMS & NDPH

Antibiotics.

Incorporated in June 1998

Origin: Oxford University, Department of Pathology

Proxisense specialise in advanced sensors, diagnostics and optimisation systems to prevent downtime & equipment failure. They improve performance & efficiency of complex rotating equipment.

Incorporated in October 2016

Origin: Oxford University, Department of Engineering Science

High heat flux technology. The company will provide advanced engineering solutions to challenging thermal problems such as those that occur in fusion reactors, or high power density electronic systems.

Incorporated in April 2020

Origin: Oxford University, Thermofluids Institute

Contact: Adrian Coles

Machine learning algorithm and codes for quantum computers.

Incorporated in October 2021

Origin: Oxford University, Department of Materials

Developing mass photometry - a revolutionary new way to analyse molecules. It enables the accurate mass measurement of single molecules in solution, in their native state and without the need for labels.

Incorporated in June 2018

Origin: Oxford University, Department of Chemistry

Contact: Adam Workman

ReOx is a drug discovery company that is building on the primary research of the founding academics to develop novel treatments for disease by controlling the activity of hypoxia inducible factor (HIF).

Incorporated in May 2003

Origin: Oxford University, Department of Physiology, Anatomy and Genetics

A biotherapeutics company, established to exploit the work in Viral Hepatitis undertaken at Imperial College, London and at Oxford University through the Wellcome Trust Centre for Human Genetics.

Incorporated in July 2003

Origin: Oxford University, Wellcome Trust Centre for Human Genetics

To develop therapeutic antibodies.

Incorporated in October 2021

Origin: Oxford University, Medical Sciences

Sparks Background Image

Ready to get in touch?

Contact Us
Sparks Background Image
© Oxford University Innovation